Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
A phase 1/2 trial of Gecacitinib in non-Hodgkin lymphoma, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.
Overview
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma is a phase 1/2 interventional study registered as NCT06883526 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 60 participants planned, started 2025-05-16 and due to reach its primary completion in 2027-04. Interventions recorded: ZG005 for Injection and Gecacitinib Hydrochloride Tablets.
Similar pages
not linked directly; found by shared links- TrialStudy of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Shares Gecacitinib, Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialStudy of ZGGS18 in Patients With Advanced Solid Tumors
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialStudy of ZG005 in Patients With Advanced Solid Tumors
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialStudy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialStudy of ZGGS34 in Participants With Advanced Solid Tumors
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialDose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
- TrialPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.